Anti-Human APCS Therapeutic Antibody
Recombinant Human monoclonal antibody expressed in CHO binding to Human APCS. Anti-SAP antibody treatment is clinically feasible because circulating human SAP can be depleted in patients by the bis-D-proline compound, CPHPC4, thereby enabling injected anti-SAP antibodiess to reach residual SAP in the amyloid deposits. The unprecedented capacity of this novel combined therapy to eliminate amyloid deposits should be applicable to all forms of systemic and local amyloidosis.
| Supplier | Creative Biolabs |
|---|---|
| Product # | TAB-047CL |
| Pricing | Inquiry |
| Host | Human |
| Target | APCS |
| Species Reactivity | Human |
| Type | Antibody |
| Storage | ≤1 year at -20°C. |